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1. INTRODUCTION {#cas14421-sec-0001}
===============

Esophageal carcinoma is the sixth most common cause of cancer‐related death worldwide.[^1^](#cas14421-bib-0001){ref-type="ref"} Esophageal squamous cell carcinoma (ESCC) is the most common histological subtype of esophageal cancer in many countries, including Japan.[^2^](#cas14421-bib-0002){ref-type="ref"}, [^3^](#cas14421-bib-0003){ref-type="ref"} Although multimodality therapies for ESCC have shown progress, patient outcome remains poor, with 5‐year overall survival rates ranging from 15% to 20%.[^4^](#cas14421-bib-0004){ref-type="ref"}, [^5^](#cas14421-bib-0005){ref-type="ref"} Cisplatin in combination with fluorouracil as first‐line therapy followed by docetaxel or paclitaxel as second‐line therapy with or without radiation is commonly used as a standard chemotherapy for metastatic ESCC in Japan.[^6^](#cas14421-bib-0006){ref-type="ref"} However, no treatment strategy has been established for ESCC patients who are refractory or intolerant to these standard therapies.

Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of melanoma, and their efficacy has also been reported in other cancers, including ESCC.[^7^](#cas14421-bib-0007){ref-type="ref"}, [^8^](#cas14421-bib-0008){ref-type="ref"}, [^9^](#cas14421-bib-0009){ref-type="ref"} Targeting of immune checkpoint proteins, such as programmed death 1 (PD‐1), and its ligand‐1 (PD‐L1) results in a continuous and significant clinical effect with low toxicity in some responder patients.[^10^](#cas14421-bib-0010){ref-type="ref"}, [^11^](#cas14421-bib-0011){ref-type="ref"}, [^12^](#cas14421-bib-0012){ref-type="ref"}, [^13^](#cas14421-bib-0013){ref-type="ref"}, [^14^](#cas14421-bib-0014){ref-type="ref"} Since March 2020, nivolumab, as a representative ICI targeting PD‐1, has been covered by the medical insurance system for ESCC in Japan. In contrast, almost all non--responder patients show no benefits on expensive ICI, accompanied by adverse immune‐related events.[^15^](#cas14421-bib-0015){ref-type="ref"} Kato et al[^9^](#cas14421-bib-0009){ref-type="ref"} showed that the disease control rate for patients who received nivolumab treatment was 37%, and the fraction of non--responder patients was 55% in ESCC. Moreover, Stephane et al[^16^](#cas14421-bib-0016){ref-type="ref"} report that ICI may have a deleterious effect in a subset of patients by accelerating disease, referred to as "hyper‐progressive disease." Thus, useful biomarkers to estimate the sensitivity of patients to ICI are required in the clinic. Several recent studies have reported candidate biomarkers for estimating sensitivity to ICI, including tumor immune status (based on PD‐L1‐positive tumor cells and CD8 tumor infiltrating lymphocytes), tumor mutation burden, and interferon‐γ (IFN‐γ) gene signature.[^17^](#cas14421-bib-0017){ref-type="ref"}, [^18^](#cas14421-bib-0018){ref-type="ref"}, [^19^](#cas14421-bib-0019){ref-type="ref"} Tumor immune status with high PD‐L1 expression/high numbers of infiltrating immune cells represents an ICI‐sensitive "hot tumor," whereas tumor immune status with low PD‐L1 expression/poor infiltration of immune cells is considered a "cold tumor" and is associated with poor local immune response and ICI resistance.[^20^](#cas14421-bib-0020){ref-type="ref"}, [^21^](#cas14421-bib-0021){ref-type="ref"} Non--invasive diagnostic methods that can distinguish hot and cold tumor statuses based on PD‐L1 expression/infiltrating immune cells remain to be established.

Glucose and amino acid metabolism in tumor cells play crucial roles in the regulation of local anti--tumor immunity.[^22^](#cas14421-bib-0022){ref-type="ref"} The 2‐deoxy‐2‐\[fluorine‐18\] fluoro‐[d]{.smallcaps}‐glucose with positron emission tomography (^18^F‐FDG PET) imaging modality based on glucose metabolism has been widely used for diagnosing malignant lesions.[^23^](#cas14421-bib-0023){ref-type="ref"} Overexpression of glucose transporter 1 (GLUT1) is reported to be significantly correlated with ^18^F‐FDG uptake in human cancers.[^24^](#cas14421-bib-0024){ref-type="ref"} Recent studies have shown that PD‐L1 expression in tumor cells is closely correlated with the uptake of ^18^F‐FDG and GLUT1 expression in patients with non--small‐cell lung cancer.[^25^](#cas14421-bib-0025){ref-type="ref"}, [^26^](#cas14421-bib-0026){ref-type="ref"} Heiden et al[^27^](#cas14421-bib-0027){ref-type="ref"} used genome‐wide expression analyses and demonstrated that esophageal adenocarcinoma tumors with high FDG uptake are significantly associated with PD‐L1 expression. Another study showed that L‐\[3‐^18^F\]‐α‐methyltyrosine (^18^F‐FAMT) PET, which is based on amino acid metabolism and is associated with the L‐type amino acid transporter 1 (LAT1), is useful in the detection of various neoplasms.[^28^](#cas14421-bib-0028){ref-type="ref"} Previously, we reported the usability of ^18^F‐FAMT PET in the diagnosis of ESCC.[^29^](#cas14421-bib-0029){ref-type="ref"}, [^30^](#cas14421-bib-0030){ref-type="ref"} However, the relationship between the tumor immune status and cancer metabolism in ESCC remains unknown.

The present study aimed to clarify the association between local anti--tumor immunity and glucose and amino acid metabolism in ESCC. Therefore, we examined ^18^F‐FDG and ^18^F‐FAMT uptake in PET imaging and the expression levels of PD‐L1, CD8, GLUT1 and LAT1 in ESCC tissue samples using immunohistochemistry to determine whether non--invasive PET imaging results can be used as a predictive biomarker for tumor immune status to identify cases with probable ICI sensitivity.

2. MATERIALS AND METHODS {#cas14421-sec-0002}
========================

2.1. Patients {#cas14421-sec-0003}
-------------

A total of 41 patients with pathologically confirmed ESCC who underwent surgical resection from April 2008 to December 2011 at Gunma University Hospital were included in this study. Samples and medical records of the same patients included in the previous study[^30^](#cas14421-bib-0030){ref-type="ref"} were used. All patients received a pre--treatment work‐up with imaging studies including ^18^F‐FDG PET and ^18^F‐FAMT PET. None of the patients received chemotherapy or radiotherapy preoperatively or had any concomitant malignancy or heart disease. Staging was based on the 7th edition of the TNM classification system of the Union for International Cancer Control. The follow‐up duration for censored cases ranged from 3.8 to 129 months (median: 60.6 months). This study conformed to the tenets of the Helsinki Declaration and was approved by the Institutional Review Board for Clinical Research at the Gunma University Hospital (Maebashi, Gunma, Japan; approval number: HS2019‐213). Patient agreement was obtained with the opt‐out method.

2.2. Immunohistochemistry {#cas14421-sec-0004}
-------------------------

Four‐micron sections were cut from paraffin blocks of all 41 samples. Each section was mounted on a silane‐coated glass slide, deparaffinized in xylene, rehydrated, and incubated for 30 minutes at room temperature in 0.3% hydrogen peroxide to block endogenous peroxidases. After rehydration through a graded series of ethanol treatments, antigen retrieval was performed in Immunosaver (Nisshin EM) at 98‐100°C for 45 minutes. Nonspecific binding sites were blocked by incubating with Protein Block Serum‐Free (Dako) for 30 minutes at room temperature. Samples were incubated overnight at 4°C with the following primary antibodies overnight: PD‐L1 (E1L3N Rabbit mAb, 1:100 dilution, Cell Signaling), CD8 (ab4055, 1:1500 dilution, Abcam), GLUT1 (ab15309, 1:200 dilution, Abcam), LAT1 (4A2, 1:3200 dilution, J‐Pharma), Ki‐67 (1:40 dilution, Dako) and CD34 (1:800 dilution, Nichirei). A Histofine Simple Stain MAX‐PO (Multi) Kit (Nichirei) was used as the secondary antibody. We applied chromogen 3,3‐diaminobenzidine tetrahydrochloride as a 0.02% solution in 50 mmol/L ammonium acetate‐citrate acid buffer (pH 6.0) containing 0.005% H~2~O~2~. The sections were lightly counterstained with hematoxylin and mounted.

Programmed death ligand‐1 expression was evaluated as positive when membrane staining was observed. A semi‐quantitative scoring method was used for PD‐L1based on a previous study: 1 ≤ 1%, 2 = 1%‐5%, 3 = 6%‐10%, 4 = 11%‐25%, 5 = 26%‐50% and 6 ≥ 50% of positive cells.[^25^](#cas14421-bib-0025){ref-type="ref"} Tumors with a score ≥3 were graded as high PD‐L1 expression. CD8 was semi‐quantitatively evaluated based on the extent of positive lymphocytes infiltrating the ESCC specimens; we defined patients with more than 5% positive lymphocytes as positive for CD8. Although definite cut‐off value rates of PD‐L1 and CD8 expression that indicated hot tumor immune status were not defined, we designated patients with more than 5% positive tumor cells of PD‐L1 and more than 5% CD8 positive tumor infiltrating lymphocytes as having hot tumor immune status in this study. For GLUT1 and LAT1, a semi‐quantitative scoring method was used as follows: 1 ≤ 10%, 2 = 11%‐25%, 3 = 26%‐50%, 4 = 51%‐75% and 5 ≥ 76% of tumor area stained. Tumors with scores of 4 or 5 were defined as high expression. For Ki‐67, we examined a highly cellular area of the immunostained sections. Epithelial cells with nuclear staining of any intensity were defined as high expression. We counted approximately 1000 nuclei on each slide. Proliferative activity was assessed as the percentage of Ki‐67‐stained nuclei (Ki‐67 labelling index) in the sample. The median value of the Ki‐67 labelling index was 41% (range, 10%‐80%). The number of CD34‐positive vessels was counted in four selected hotspots in a 400× field (0.26 mm^2^ field area). CD34‐positive vessel counts were defined as the mean microvessel counts per 0.26 mm^2^ field area. These evaluation methods are based on previous studies.[^30^](#cas14421-bib-0030){ref-type="ref"}, [^31^](#cas14421-bib-0031){ref-type="ref"}

The tissue sections were examined under a light microscope by two independent investigators who were blinded to the patient data. In case of discrepancies, both investigators examined the slides simultaneously until a final consensus on the assessment was obtained.

2.3. Positron emission tomography imaging and data analysis {#cas14421-sec-0005}
-----------------------------------------------------------

We synthesized ^18^F‐FAMT in our cyclotron facility according to a previously described method.[^28^](#cas14421-bib-0028){ref-type="ref"} The radiochemical yield of ^18^F‐FAMT was approximately 20%, and the radiochemical purity was approximately 99%. We also produced ^18^F‐FDG in our facility as described previously.[^32^](#cas14421-bib-0032){ref-type="ref"} The patients fasted for at least 6 hours before PET imaging. One of two PET/CT scanners (Discovery STE, GE Healthcare; Biograph 16, SIEMENS Healthcare) was randomly selected with a 700‐mm field of view. Three‐dimensional data acquisition was initiated 50 minutes after the injection of 5 MBq/kg of ^18^F‐FAMT or 5 MBq/kg of ^18^F‐FDG. We acquired 4‐10 bed positions (3 minutes acquisition per bed position) according to the range of imaging. Attenuation‐corrected transverse images obtained with ^18^F‐FAMT and ^18^F‐FDG were reconstructed using the ordered‐subset expectation maximization algorithm into 128 × 128 matrices with a slice thickness of 3.27 mm. All ^18^F‐FAMT and ^18^F‐FDG PET images were evaluated by two experienced nuclear physicians. Tracer uptake in the primary tumor was defined as a positive finding if the uptake was higher than that in the normal mediastinum. Any discrepant results were resolved by consensual review. For semiquantitative analysis, functional images of the standardized uptake value (SUV) were produced based on the attenuation‐corrected transaxial images, the injected doses of ^18^F‐FAMT and ^18^F‐FDG (MBq), the patients' body weight (g), and the cross‐calibration factor between PET and the dose calibrator. The SUV (MBq/g) of the lesion was defined as the radioactive concentration in the region of interest (ROI) divided by the injected dose (MBq) and the patient's body weight (g). The ROI was manually drawn over the primary tumor on the SUV images. When the tumor was \>1 cm in diameter or if the shape of the tumor was irregular or multifocal, a ROI of approximately 1 cm in diameter was drawn over the area corresponding to the maximal tracer uptake. ROI analysis was performed by a nuclear physician with the aid of the corresponding CT scans. The maximal SUV in the ROI (SUVmax) was used as a representative uptake value for evaluating the ^18^F‐FAMT and ^18^F‐FDG uptake in the primary lesion for statistical analyses.

2.4. Statistical analysis {#cas14421-sec-0006}
-------------------------

Statistical analyses were performed with the Mann‐Whitney *U* test for continuous variables and the χ^2^‐test for categorical variables. The correlation between SUVmax for ^18^F‐FAMT and ^18^F‐FDG on PET and different variables was analyzed using Spearman's correlation coefficient tests. Kaplan‐Meier curves were used for overall survival, and statistical significance was determined using the log‐rank test. Univariate analysis was performed with each predictive factor using logistic regression analysis for a hot tumor immune status, defined as high PD‐L1 and high CD8‐positive lymphocytes in ESCC tissues. Receiver operating characteristic (ROC) curve analyses were used to evaluate the potential of SUVmax for ^18^F‐FAMT and ^18^F‐FDG to discriminate between hot tumor immune status and others. Sensitivity and specificity were calculated to detect the optimal cut‐off value for the SUVmax using ROC curves. A probability value of \<0.05 was considered significant. All statistical analyses were performed using JMP software (SAS Institute).

3. RESULTS {#cas14421-sec-0007}
==========

3.1. Immunohistochemical staining for programmed death ligand‐1 and CD8 in clinical esophageal squamous cell carcinoma samples {#cas14421-sec-0008}
------------------------------------------------------------------------------------------------------------------------------

In total, 41 patients with ESCC were enrolled in this study. PD‐L1 immunostaining was detected in cancer cells and localized predominantly on the plasma membrane. PD‐L1 expression levels in cancer tissues were higher than those in normal tissues (Figure [1A](#cas14421-fig-0001){ref-type="fig"}). CD8‐positive lymphocytes were observed more frequently around cancer tissues than around normal tissues (Figure [1B](#cas14421-fig-0001){ref-type="fig"}). Representative images of ^18^F‐FDG PET and ^18^F‐FAMT PET in the same case of Figure [1A,B](#cas14421-fig-0001){ref-type="fig"} are shown in Figure [1C,D](#cas14421-fig-0001){ref-type="fig"}. The rates of high PD‐L1 and CD8 expression were 53.7% (22/41) and 34.1% (14/41), respectively. Approximately 31.7% (13/41) of samples in this cohort showed hot tumor immune status. High levels of GLUT1 and LAT1 were identified in 68.3% (28/41) and 43.9% (18/41) of cases, respectively. The median Ki‐67 labelling index was 41% (range, 10%‐80%). The median number of CD34‐positive vessels was 18 (range 5‐35).

![Representative immunohistochemical staining and positron emission tomography (PET) imaging of patients with esophageal squamous cell carcinoma (ESCC). Representative immunostaining for programmed death ligand‐1 (PD‐L1) (A, original magnification 200×) and CD8 (B, original magnification 100×) expression in slides containing both ESCC and normal tissue (scale bar = 100 μm). PET imaging of ^18^F‐FDG (C) and ^18^F‐FAMT (D) in the same patient is shown](CAS-111-1969-g001){#cas14421-fig-0001}

3.2. Clinicopathological significance of programmed death ligand‐1, CD8 and tumor immune status in esophageal squamous cell carcinoma {#cas14421-sec-0009}
-------------------------------------------------------------------------------------------------------------------------------------

The correlations between clinicopathological characteristics of ESCC patients and PD‐L1, CD8 and hot tumor immune status are described in Table [1](#cas14421-tbl-0001){ref-type="table"}. High PD‐L1 expression was significantly associated with tumor invasion (*P* = 0.028), lymphatic invasion (*P* = 0.032), venous invasion (*P* = 0.018), stage (*P* = 0.041), CD8 expression (*P* \< 0.001), GLUT1 expression (*P* \< 0.001), LAT1 expression (*P* = 0.006), Ki‐67 labelling index (*P* = 0.009) and CD34‐positive vessel count (*P* \< 0.001). High CD8 expression was correlated with high PD‐L1 expression (*P* \< 0.001) and a high Ki‐67 labelling index (*P* = 0.005). Hot tumor immune status (with high PD‐L1 and high CD8) was significantly associated with high GLUT1 expression (*P* = 0.024) and a high Ki‐67 labelling index (*P* = 0.014).

###### 

Association of clinicopathological features and programmed death ligand‐1 (PD‐L1) expression, CD8 expression, and hot tumor immune status in 41 esophageal squamous cell carcinoma (ESCC) patients

  Factor                         PD‐L1 expression   *P* value     CD8 expression   *P* value     Tumor immune status   *P* value                               
  ------------------------------ ------------------ ------------- ---------------- ------------- --------------------- ----------- ------------- ------------- ------
  Age (y)                                                                                                                                                      
  Mean ± SD                      67.7 ± 7.1         65.6 ± 6.3    .32              67.0 ± 6.8    65.9 ± 6.7            .64         65.4 ± 6.6    67.2 ± 6.7    .43
  Sex                                                                                                                                                          
  Male                           15                 21            .11              23            13                    .48         12            24            .55
  Female                         4                  1             4                1             1                     4                                       
  Tumor invasion                                                                                                                                               
  T1, T2                         15                 10            .028             17            8                     .717        7             18            .524
  T3, T4                         4                  12            10               6             6                     10                                      
  N factor                                                                                                                                                     
  Absent                         9                  5             .097             9             5                     .879        4             10            .756
  Present                        10                 17            18               9             9                     18                                      
  Lymphatic invasion                                                                                                                                           
  Absent                         7                  2             .032             6             3                     .954        2             7             .489
  Present                        12                 20            21               11            11                    21                                      
  Venous invasion                                                                                                                                              
  Absent                         9                  3             .018             9             3                     .427        3             9             .553
  Present                        10                 19            18               11            10                    19                                      
  Stage                                                                                                                                                        
  Stage I, II                    13                 8             .041             15            6                     .441        5             16            .266
  Stage III, IV                  6                  14            12               8             8                     12                                      
  PD‐L1 expression                                                                                                                                             
  Low                            --                 --            --               18            1                     \<.001      --            --            --
  High                           --                 --            9                13            --                    --                                      
  CD8 positive lymphocytes                                                                                                                                     
  Low                            18                 9             \<.001           --            --                    --          --            --            --
  High                           1                  13            --               --            --                    --                                      
  GLUT1                                                                                                                                                        
  Low                            11                 2             \<.001           11            2                     .084        1             12            .024
  High                           8                  20            16               12            12                    16                                      
  LAT1                                                                                                                                                         
  Low                            15                 8             .006             16            7                     .571        6             17            .382
  High                           4                  14            11               7             7                     11                                      
  Ki‐67 labeling index                                                                                                                                         
  Mean ± SD                      36.8 ± 19.2        52.4 ± 17.6   .009             39.1 ± 18.2   56.7 ± 17.8           .005        56.1 ± 18.3   40.1 ± 18.6   .014
  CD34 positive vessels counts                                                                                                                                 
  Mean ± SD                      13.9 ± 5.3         22.1 ± 5.9    \<.001           17.0 ± 7.0    21.0 ± 6.0            .075        20.9 ± 6.2    17.1 ± 7.0    .103
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Figure [2](#cas14421-fig-0002){ref-type="fig"} presents the prognostic analyses of ESCC patients according to PD‐L1 expression (Figure [2A](#cas14421-fig-0002){ref-type="fig"}), CD8 expression (Figure [2B](#cas14421-fig-0002){ref-type="fig"}) and hot tumor immune status (Figure [2C](#cas14421-fig-0002){ref-type="fig"}). ESCC patient groups with high PD‐L1, high CD8 or hot tumor immune status were not associated with poor prognosis compared to the other groups.

![Overall survival of the study population according to programmed death ligand‐1 (PD‐L1) expression, CD8 expression and hot tumor immune status. A, Overall survival of esophageal squamous cell carcinoma (ESCC) patients according to tumoral PD‐L1 expression. B, Overall survival of ESCC patients according to infiltrating CD8‐positive lymphocytes. C, Overall survival of ESCC patients according to hot tumor immune status defined as high tumoral PD‐L1 expression and high infiltrating CD8‐positive lymphocytes in ESCC tissues. ESCC patient groups with high PD‐L1, high CD8 or hot tumor immune status were not associated with poor prognosis compared to the other groups](CAS-111-1969-g002){#cas14421-fig-0002}

3.3. Relationship between ^18^F‐FDG/^18^F‐FAMT uptake and immune status of esophageal squamous cell carcinoma {#cas14421-sec-0010}
-------------------------------------------------------------------------------------------------------------

Figure [3](#cas14421-fig-0003){ref-type="fig"} shows the relationship between PET tracer uptake and immune status of ESCC. The SUVmax of ^18^F‐FDG in the high PD‐L1 group was significantly higher than that in the low PD‐L1 group (*P* = 0.009) (Figure [3A](#cas14421-fig-0003){ref-type="fig"}). CD8 expression and hot tumor immune status showed a tendency to be related with high SUVmax of ^18^F‐FDG (*P* = 0.063 and *P* = 0.057, respectively) (Figure [3A](#cas14421-fig-0003){ref-type="fig"}). The SUVmax values of ^18^F‐FAMT in the high PD‐L1, high CD8 and hot tumor groups were significantly higher than those in the other groups (*P* \< 0.001, *P* = 0.012 and *P* = 0.028, respectively) (Figure [3B](#cas14421-fig-0003){ref-type="fig"}).

![Relationship between positron emission tomography (PET) tracer uptake and programmed death ligand‐1 (PD‐L1), CD8 and hot tumor immune status in esophageal squamous cell carcinoma tissues. A, Correlation between SUVmax of ^18^F‐FDG and PD‐L1, CD8 and hot tumor immune status. SUVmax of ^18^F‐FDG in high PD‐L1 cases was significantly higher than that in low PD‐L1 cases (*P* = 0.009). B, Correlation between SUVmax of ^18^F‐FAMT and PD‐L1, CD8 and hot tumor immune status. The SUVmax of ^18^F‐FAMT in the high PD‐L1, high CD8 and hot tumor groups was significantly higher than that in the other groups (*P* \< 0.001, *P* = 0.012 and *P* = 0.028, respectively)](CAS-111-1969-g003){#cas14421-fig-0003}

3.4. Diagnostic value of ^18^F‐FAMT uptake in predicting the hot tumor immune status in esophageal squamous cell carcinoma {#cas14421-sec-0011}
--------------------------------------------------------------------------------------------------------------------------

We next analyzed the diagnostic value of clinicopathological factors and PET imaging to estimate the hot tumor immune status in the ESCC cohort. ROC analysis for the SUVmax of ^18^F‐FDG revealed that the optimal cut‐off value for a hot tumor was 8.79 (area under the curve \[AUC\], 0.654; *P* = 0.05, sensitivity, 69.2%, specificity, 60.7%; Figure [4A](#cas14421-fig-0004){ref-type="fig"}), and ROC analysis for the SUVmax of ^18^F‐FAMT showed a cut‐off value of 4.15 (AUC, 0.701; *P* = 0.025, sensitivity, 38.5%, specificity, 92.9%; Figure [4B](#cas14421-fig-0004){ref-type="fig"}). The ESCC patients were divided into high and low groups according to these cut‐off points. The high SUVmax of ^18^F‐FAMT by non--invasive ^18^F‐FAMT‐PET was the only predictive factor for the hot tumor immune status (OR, 0.12; 95% CI, 0.02‐0.69; *P* = 0.02; Table [2](#cas14421-tbl-0002){ref-type="table"}). The other clinicopathological factors were not significantly associated with hot tumor immune status. Using the cut‐off value of 4.15 for the SUVmax of ^18^F‐FAMT, the accuracy rate of ^18^F‐FAMT‐PET that predicts hot tumor immune status was 75.6%, and the positive predictive value was 71.4%.

![Receiver operating characteristic (ROC) curve analyses for the optimal cut‐off value of positron emission tomography (PET) tracer uptake. ROC analyses for the potential of SUVmax for ^18^F‐FDG (A) and ^18^F‐FAMT (B) to discriminate between hot tumor immune status and others. The areas under the curve for hot tumor immune status were 0.654 and 0.701 for SUVmax of ^18^F‐FDG and ^18^F‐FAMT, respectively](CAS-111-1969-g004){#cas14421-fig-0004}

###### 

Univariate analysis of factors associated with hot tumor immune status

  Clinicopathologic variable            Univariate analysis   *P* value   
  ------------------------------------- --------------------- ----------- -----
  Age (≤65/\>65 y)                      1.35                  0.36‐5.19   .66
  Sex (male/female)                     2                     0.26‐41.4   .53
  T factor (T1, T2/T3, T4)              0.65                  0.17‐2.51   .53
  N factor (absent/present)             0.8                   0.18‐3.18   .76
  Lymphatic invasion (absent/present)   0.55                  0.07‐2.74   .48
  Venous invasion (absent/present)      0.63                  0.12‐2.7    .55
  SUVmax of ^18^F‐FDG (low/high)        0.29                  0.06‐1.11   .07
  SUVmax of ^18^F‐FAMT (low/high)       0.12                  0.02‐0.69   .02

CI, confidence interval; OR, odds ratio.
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4. DISCUSSION {#cas14421-sec-0012}
=============

In this study, we demonstrated that high expression levels of PD‐L1 in ESCC were significantly associated with the progression of tumor invasion, lymphatic invasion, venous invasion, stage, CD8‐positive lymphocytes, GLUT1 expression, LAT1 expression, Ki‐67 labelling index, and CD34‐positive vessel count. In addition, we showed that the SUVmax of ^18^F‐FDG was significantly correlated with PD‐L1 expression, and the SUVmax of ^18^F‐FAMT was significantly associated with high PD‐L1, high CD8 expression, and hot tumor immune status. The high SUVmax of ^18^F‐FAMT was the only predictor of the hot tumor phenotype.

The efficacy of ICI is affected by PD‐L1 expression of the tumor, as well as by the local anti--tumor immunity of cancer patients. Tumors with a higher density of infiltrating immune cells, called hot tumors, are more responsive to ICI than cold tumors with a lower density of infiltrating immune cells.[^20^](#cas14421-bib-0020){ref-type="ref"}, [^21^](#cas14421-bib-0021){ref-type="ref"} In ESCC, the usability of PD‐L1 expression as a biomarker of ICI sensitivity remains controversial.[^9^](#cas14421-bib-0009){ref-type="ref"}, [^33^](#cas14421-bib-0033){ref-type="ref"} However, in other cancers, several studies have reported the predictive value of ICI sensitivity markers, such as tumoral PD‐L1 expression,[^34^](#cas14421-bib-0034){ref-type="ref"} hot tumor phenotype,[^20^](#cas14421-bib-0020){ref-type="ref"}, [^21^](#cas14421-bib-0021){ref-type="ref"} tumor mutation burden[^35^](#cas14421-bib-0035){ref-type="ref"} and IFN‐γ gene signature.[^36^](#cas14421-bib-0036){ref-type="ref"}, [^37^](#cas14421-bib-0037){ref-type="ref"} In our study, we examined the expression of not only PD‐L1 but also CD8‐positive lymphocyte infiltration in ESCC to indicate hot tumor immune status and demonstrated a positive correlation between PET‐imaging results and hot tumor phenotype in ESCC. These data suggested that PET‐imaging as a predictor of PD‐L1 and CD8 expression may be associated with ICI sensitivity in ESCC. However, we could not estimate a direct association between ICI sensitivity, local anti--tumor immunity, and PET imaging in our cohort without ICI treatment. Further studies are thus required to evaluate the clinical significance of PET imaging as an ICI sensitivity marker in ESCC patients who have received ICI therapy.

In ESCC recurrence cases, especially in mediastinal or abdominal lymph node recurrence, obtaining tumor samples is difficult. As mentioned above, PD‐L1 expression, hot tumor phenotype, tumor mutation burden and an IFN‐γ gene signature were related to ICI sensitivity in several cancers. However, invasive procedures may be needed to obtain sufficient tumor tissues to evaluate these factors in patients with profound recurrent tumors in the thoracic or abdominal cavity. Although local immune status may be easily evaluable in primary tumors resected before recurrence, the primary tumor and metastatic/recurrent lesions may show differences in phenotype and tumor immune status. The heterogeneity of PD‐L1 status between the primary cancer lesion and metastatic lymph nodes has been reported in triple negative breast cancer, clear cell renal cancer and bladder cancer.[^38^](#cas14421-bib-0038){ref-type="ref"}, [^39^](#cas14421-bib-0039){ref-type="ref"}, [^40^](#cas14421-bib-0040){ref-type="ref"} In addition, the tumor tissue obtained from the previous surgical treatment for the primary site may be considered old in comparison with that obtained from the current profound recurrent lymph node. Therefore, real‐time monitoring of immune status in metastatic/recurrent tumors is difficult using the existing techniques. Moreover, patients with advanced ESCC often show poor performance status because of poor oral intake, low nutrient condition, and cachexia; invasive procedures in such patients may cause severe adverse events. In our study, we showed that high uptake of ^18^F‐FDG and ^18^F‐FAMT by non--invasive PET imaging was significantly associated with a hot tumor phenotype, which has been associated with good response to ICI treatment in several cancers. These results suggest that non--invasive PET imaging can help evaluate the real‐time expression of PD‐L1 and CD8 in target lesions, independent of problems caused by temporal and spatial heterogeneity between the primary site and metastatic/recurrent lesions. This suggests the possibility of selecting ESCC patients who can receive the benefits of ICI without invasive tumor sampling.

Glucose and amino acid metabolism in tumor cells play crucial roles in the regulation of PD‐L1 expression, which is important for anti--tumor immunity.[^22^](#cas14421-bib-0022){ref-type="ref"} GLUT1 and LAT1 are widely expressed in various human cancers,[^41^](#cas14421-bib-0041){ref-type="ref"}, [^42^](#cas14421-bib-0042){ref-type="ref"}, [^43^](#cas14421-bib-0043){ref-type="ref"}, [^44^](#cas14421-bib-0044){ref-type="ref"}, [^45^](#cas14421-bib-0045){ref-type="ref"}, [^46^](#cas14421-bib-0046){ref-type="ref"} and PET tracers such as ^18^F‐FDG and ^18^F‐FAMT are imported to tumor cells via GLUT1 and LAT1, respectively.[^24^](#cas14421-bib-0024){ref-type="ref"}, [^47^](#cas14421-bib-0047){ref-type="ref"}, [^48^](#cas14421-bib-0048){ref-type="ref"}, [^49^](#cas14421-bib-0049){ref-type="ref"} High expression of LAT1 in cancer tissues can activate HIF‐1α/GLUT1 signaling through activation of mammalian target of rapamycin (mTOR).[^50^](#cas14421-bib-0050){ref-type="ref"}, [^51^](#cas14421-bib-0051){ref-type="ref"}, [^52^](#cas14421-bib-0052){ref-type="ref"} Interestingly, Noman et al report that HIF‐1α directly binds to the hypoxia‐responsive element in the proximal promoter of PD‐L1 and can upregulate PD‐L1 expression.[^53^](#cas14421-bib-0053){ref-type="ref"} In our study, we demonstrated that PD‐L1 expression in ESCC tissues was significantly correlated with the expression of GLUT1 and LAT1 (Table [1](#cas14421-tbl-0001){ref-type="table"} and Figure [S1](#cas14421-sup-0001){ref-type="supplementary-material"}). Moreover, our previous study showed that ^18^F‐FDG and ^18^F‐FAMT uptake in PET imaging is significantly associated with the expression levels of transporters for glucose and amino acids, such as GLUT1 and LAT1.[^30^](#cas14421-bib-0030){ref-type="ref"} These results suggest that PET imaging for visualizing glucose and amino acid metabolism might reflect the expression levels of PD‐L1 in local ESCC tissues through activation of the LAT1/HIF1α/GLUT1/PD‐L1 axis.

In our study, there was a statistically significant association between high PD‐L1 expression and Ki‐67 labeling index or CD34 positive vessel counts: activating receptor tyrosine kinase (RTK) or HIF1α induced PD‐L1.[^54^](#cas14421-bib-0054){ref-type="ref"}, [^55^](#cas14421-bib-0055){ref-type="ref"} RTK activation upregulates the proliferative capacity of tumor cells, while HIF1α plays a crucial role in angiogenesis by mediating vascular endothelial growth factor.[^52^](#cas14421-bib-0052){ref-type="ref"} Several studies have reported that the expression of PD‐L1 is significantly correlated with proliferation ability and angiogenesis in cancer cells.[^56^](#cas14421-bib-0056){ref-type="ref"}, [^57^](#cas14421-bib-0057){ref-type="ref"}, [^58^](#cas14421-bib-0058){ref-type="ref"} Our study suggested that high PD‐L1 ESCC patients had upregulated proliferation capacity and angiogenesis through RTK or HIF1α activation.

Our study also shows the association between ^18^F‐FAMT uptake and CD8 positive lymphocyte infiltration, which constitutes the indispensable element of hot tumors. LAT1 transports abundant neutral amino acids, such as tyrosine, leucine and tryptophan, into the cell.[^59^](#cas14421-bib-0059){ref-type="ref"} Tryptophan is an essential amino acid that is metabolized through the kynurenine pathway, which is mainly catalyzed by indoleamine 2,3‐dioxygenase.[^60^](#cas14421-bib-0060){ref-type="ref"} Tryptophan deprivation causes immunosuppression due to the increased demand for tryptophan during T cell activation.[^22^](#cas14421-bib-0022){ref-type="ref"} However, the relationship between ^18^F‐FAMT‐PET, LAT1 and tryptophan metabolism in ESCC has many ambiguities. Therefore, further studies are needed to clarify whether high uptake of ^18^F‐FAMT that depends on LAT1 can predict CD8 infiltration through tryptophan metabolism.

This study had several limitations. First, this was a retrospective single institution study, and we only enrolled patients without ICI treatment, such as nivolumab or pembrolizumab, and those who had undergone surgical resection, creating an unavoidable bias. Second, the number of patients in the study was small. Third, we did not perform any functional experiments on the associations among tumor PD‐L1 expression, CD8‐positive lymphocytes, and uptake of ^18^F‐FDG and ^18^F‐FAMT using in vitro and in vivo analyses.

In conclusion, we demonstrated that high uptake of PET tracers, such as ^18^F‐FDG and ^18^F‐FAMT, was correlated with PD‐L1 and CD8 expression in ESCC. In addition, high level of ^18^F‐FAMT uptake was the only predictor of hot tumor immune status in ESCC, as indicated by high PD‐L1 expression and increased CD8‐positive lymphocytes. These observations suggest that PET imaging may be a good diagnostic tool to predict tumor immune status in ESCC cases associated with ICI sensitivity. Nonetheless, further studies are warranted to clarify the direct relationship between PET imaging and ICI treatment.
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